Show results for
Refine by
Cancer With Personalized Testing Suppliers Serving Canada
34 companies found
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA ...
based inLondon, UNITED KINGDOM
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the ...
based inFrankfurt, GERMANY
NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer. The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. ...
based inNewark, CALIFORNIA (USA)
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...
based inBoston, MASSACHUSETTS (USA)
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of ...
based inNew York, NEW YORK (USA)
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management ...
The science behind miR’s prostate and bladder cancer detection and classification technology that can help give healthcare providers, patients, and payors the greatest confidence in test results and care ...
based inCortlandt Manor, NEW YORK (USA)
Polymedco is dedicated to enhancing early detection of life-threatening diseases as healthcare challenges intensify due to rising chronic disease rates, an aging population, and soaring medical costs. The company collaborates with healthcare ...
OC-Auto FIT is a fecal immunochemical test (FIT) designed to enhance colorectal cancer screening by offering a highly accurate and clinically supported method. The test is geared towards individuals aged 45 to 75, adhering to Tier 1 guidelines, ...
based inDoylestown, PENNSYLVANIA (USA)
Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality. Our proprietary ...
based inBerlin, GERMANY
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high ...
Colorectal cancer is curable in about 90% of cases if detected early. Nevertheless, this disease is one of the most frequent causes of cancer-related deaths in the industrialized world. Regular screening can prevent colorectal cancer. Epi ...
based inGeorgetown, TEXAS (USA)
Ezra is focused on early cancer detection through the use of full-body MRI scans. Given that early detection significantly increases survival rates, Ezra's annual Full Body Scans aim to identify cancer signs early, potentially preventing late-stage ...
Ezra offers advanced MRI-based full-body scans aimed at early cancer detection. The service employs 3 Tesla (3T) MRI technology, known for its higher-resolution imaging and superior signal-to-noise ratio, alongside 1.5 Tesla (1.5T) MRI for broader ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
The OTraces technology platform drives multiple business opportunities. The software is embedded into a laboratory information management system (LIMS) wherein all patient and instrument data is stored in secure U.S. based servers. This software is ...
based inRedwood City, CALIFORNIA (USA)
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We’re developing blood tests for early detection in high-risk populations and ...
based inDunedin,, NEW ZEALAND
Pacific Edge is a cancer diagnostics company. We specialise in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer. Our ...
Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer. The tests works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer1, and comes as a ...
based inNew York, NEW YORK (USA)
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We have the brightest people in the industry and believe that their diverse ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inGaithersburg, MARYLAND (USA)
20/20 GeneSystems Inc. develops and commercializes diagnostic tests for the early detection of cancer to improve outcomes of people at high risk for specific types of cancers. It offers blood tests for use in the United States to aid in the early ...
based inOsaka, JAPAN
Alfresa Pharma develops, manufactures, and sells diagnostic reagents and equipments used in hospital laboratories and group medical examinations, with the mission of “delivering unprecedented new in vitro diagnostics.” We have applied our original ...
The conventional fecal occult blood test uses a chemical to perform the test, such as guaiac test (g-FOBT). However, our FIT Hemoglobin and Trasnferrin products use an immunoassay that reacts specifically to human hemoglobin/transferrin, eliminating ...
based inPleasanton, CALIFORNIA (USA)
Anchor Molecular is a life science diagnostics company specializing in the development of best-in-class quality controls, reference materials, and reagents for liquid biopsy assays. We focus on liquid biopsy cancer diagnostic test based on cell-free ...
based inEspoo, FINLAND
We are a leading Finnish-based in vitro diagnostics (IVD) company established in 1974. We develop, manufacture, and distribute reliable and fast CE marked diagnostic tests for point of care. Our aim is to aid global health by promoting efficient ...